Pacira BioSciences: Mispriced On Generic Risks That Are Years Away [Seeking Alpha]
Pacira BioSciences, Inc. (PCRX)
Last pacira biosciences, inc. earnings: 2/20 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.pacira.com
Company Research
Source: Seeking Alpha
EXPAREL's manufacturing complexity and hospital adoption create a significant moat, making immediate generic substitution unlikely even after patent setbacks. The NOPAIN Act introduces a major reimbursement tailwind, shifting EXPAREL from a hospital cost burden to a neutral or positive economic choice. PCRX's current 5.5x EV/EBITDA multiple reflects worst-case assumptions, offering asymmetric upside if generic threats and reimbursement risks are overstated. Jonathan Kitchen/DigitalVision via Getty Images Pacira BioSciences ( PCRX ) is arguably one of the most hated names in the specialty pharma space. If you zoom out on the chart, it looks like a business heading for a liquidity crisis. The stock has drifted This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own op
Show less
Read more
Impact Snapshot
Event Time:
PCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCRX alerts
High impacting Pacira BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
PCRX
News
- Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of DirectorsGlobeNewswire
- Do Options Traders Know Something About Pacira BioSciences Stock We Don't? [Yahoo! Finance]Yahoo! Finance
- Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific MarketsGlobeNewswire
- How Investors May Respond To Pacira BioSciences (PCRX) Activist Pressure Amid Buybacks And Rising EXPAREL Revenue [Yahoo! Finance]Yahoo! Finance
PCRX
Earnings
- 11/6/25 - Beat
PCRX
Sec Filings
- 2/3/26 - Form 4
- 2/3/26 - Form 4
- 2/3/26 - Form 4
- PCRX's page on the SEC website